Related Experiment Videos
Silent renal microangiography after mitomycin C therapy.
E Poch1, J M González-Clemente, A Torras
1Nephrology Service, Hospital Clinic i Provincial, University of Barcelona, Spain.
American Journal of Nephrology
|January 1, 1990
Summary
Mitomycin C (MMC) chemotherapy can cause severe kidney damage, even without typical blood abnormalities. Long-term monitoring of renal function is crucial for early diagnosis and management of this rare complication.
Area of Science:
- Nephrology
- Oncology
- Pharmacology
Background:
- Mitomycin C (MMC) is an alkylating agent used in chemotherapy.
- MMC is associated with a 2-10% incidence of microangiopathic hemolytic anemia and acute renal failure.
- Renal impairment without overt hemolysis is less commonly documented.